mc-val-cit-pab

MC-Val-Cit-PAB is a cathepsin cleavable ADC linker that is used for making antibody-drug conjugate. FDA approved drugs such as brentuximab vedotin use this linker.

MC-Val-Cit-PAB-Retapamulin is a drug-linker conjugate used in antibody-drug conjugates (ADC) that exhibits potent antitumor activity. It employs Retapamulin, a ribosome inhibitor, connected via the ADC linker MC-Val-Cit-PAB.

MC-Val-Cit-PAB-vinblastine is a potent antitumor drug-linker conjugate for Antibody-Drug Conjugates (ADC), featuring vinblastine (a microtubule protein inhibitor) connected through the MC-Val-Cit-PAB [ADC linker].

Mc-Val-Cit-PAB-Cl, a cleavable ADC linker, is utilized in the conjugation of MMAE and antibodies to produce compounds such as antibody-MC-vc-MMAE (e.g., anti-CD22-MC-VC-PABC-MMAE), which demonstrate cytotoxicity with IC50s of 3.3 and 0.95 nM against BJAB and WSU cell lines, respectively.

MC-Val-Cit-PAB-Sunitinib is a conjugate composed of the payload Sunitinib and a linker. It is utilized in the synthesis of HR97-Sunitinib.

MC-Val-Cit-PAB-rifabutin is a drug-linker conjugate for antibody-drug conjugates (ADC), featuring the potent antitumor agent rifabutin (a DNA-dependent RNA polymerase inhibitor) connected via the MC-Val-Cit-PAB ADC linker, which endows it with significant antitumor activity.

MC-Val-Cit-PAB-Auristatin E is an antibody-drug conjugate (ADC) linker compound with Auristatin E, a potent cytotoxic tubulin modifier, attached via the MC-Val-Cit-PAB linker, demonstrating significant antitumor activity.

MC-Val-Cit-PAB-clindamycin is an antibody-drug conjugate (ADC) linker combining the potent antitumor properties of clindamycin, a protein synthesis inhibitor, with the ADC linker MC-Val-Cit-PAB, thereby enhancing its cancer cell targeting and killing effectiveness.

MC-Val-Cit-PAB-duocarmycin is an antibody-drug conjugate (ADC) linker that combines duocarmycin, a potent DNA minor groove-binding alkylating agent, with an antitumor drug through the MC-Val-Cit-PAB linker, exhibiting significant antitumor activity.

MC-Val-Cit-PAB-carfilzomib is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADC), comprising the irreversible proteasome inhibitor carfilzomib, connected through the ADC linker MC-Val-Cit-PAB.

MC-Val-Cit-PAB-MMAF is an antibody-drug conjugate (ADC) component that exhibits antitumor properties through the action of the tubulin inhibitor, monomethyl auristatin F (MMAF), which is connected by a cathepsin-cleavable linker, MC-Val-Cit-PAB.

MC-Val-Cit-PAB-dimethylDNA31 is a drug-linker conjugate employed in antibody-drug conjugates (ADCs) that exhibits robust antitumor efficacy. This conjugate utilizes the ADC linker, MC-Val-Cit-PAB, to connect with the potent antitumor agent dimethylDNA31, which also demonstrates significant bactericidal activity against both persister and stationary-phase [Staphylococcus aureus].

MC-Val-Cit-PABC-PNP, also known as Mc-Val-Cit-PABC-PNP, is a cathepsin cleavable ADC peptide linker. For example, FDA approved drug, brentuximab vedotin, adopts this linker. Protein- and peptide-drug conjugates hold a promising stance in the delivery of therapeutic agents by providing distinct advantage of improving therapeutic potential of drugs. Use of specialized linkers makes them unique in their in vivo therapeutic application by providing target tissue-specific release of drug.

Doxorubicin-MVCP (MC-Val-Cit-PAB-Doxorubicin) is a Doxorubicin derivative with an MC-Val-Cit-PAB linker.

MC-Val-Cit-PAB-tubulysin5a is a drug-linker conjugate for ADC with potent antitumor activity by using tubulysin5a (a tubulin inhibitor), linked via the ADC linker MC-Val-Cit-PAB.

Paclitaxel-MVCP ( MC-val-cit-pab-paclitaxel )is a paclitaxel derivative with an MC-Val-Cit-PAB linker, which can be used for the preparation of Paclitaxel conjugates for drug delivery and nanomedicine research.